Bausch Health Companies (TSE:BHC) Stock: Insider Mirza Dautbegovic Sells 20,000 Shares

Bausch Health Companies Inc. (TSE:BHC) insider Mirza Dautbegovic sold 20,000 shares of Bausch Health Companies stock in a transaction that occurred on Thursday, October 29th. The stock was sold at an average price of C$11.18, for a total transaction of C$223,600.00. Following the completion of the transaction, the insider directly owned 224,745 shares in the company, valued at C$2,512,649.10. This represents a 8.17% decrease in their position.

Bausch Health Companies Price Performance

Shares of TSE BHC traded up C$0.37 during midday trading on Friday, reaching C$11.56. The company’s stock had a trading volume of 852,072 shares, compared to its average volume of 563,138. The company has a current ratio of 1.56, a quick ratio of 0.58 and a debt-to-equity ratio of -1,559.86. The company has a 50 day moving average price of C$8.99 and a 200 day moving average price of C$7.98. Bausch Health Companies Inc. has a one year low of C$6.10 and a one year high of C$12.65. The company has a market cap of C$4.33 billion, a price-to-earnings ratio of -5.12, a price-to-earnings-growth ratio of 0.21 and a beta of 0.73.

Bausch Health Companies (TSE:BHC) last issued its earnings results on Wednesday, October 28th. The company reported C$2.52 earnings per share for the quarter. The firm had revenue of C$4.19 billion during the quarter. Bausch Health Companies had a negative net margin of 7.43% and a positive return on equity of 57.67%. On average, equities research analysts expect that Bausch Health Companies Inc. will post 5.55 EPS for the current year.

Bausch Health Companies announced that its Board of Directors has approved a share repurchase plan on Wednesday, October 28th that authorizes the company to repurchase C$70 million in outstanding shares. This buyback authorization authorizes the company to repurchase up to 1.9% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s management believes its stock is undervalued.

Wall Street Analyst Weigh In

Separately, Jefferies Financial Group upgraded Bausch Health Companies to a “hold” rating in a report on Wednesday, July 22nd. Three investment analysts have rated the stock with a Hold rating. Based on data from MarketBeat, the company has an average rating of “Hold”.

Bausch Health Companies Company Profile

Bausch Health Companies Inc (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.